Parkinson’s Disease
Where human focus meets scientific execution.
The Parkinson’s Precision Principle:
Clinical programs built around people, not just protocols
Parkinson’s disease (PD) research is fueled by an extraordinary community, led by those living with the disease and navigating its uncertainty every day. People with Parkinson’s disease choose to enroll in clinical trials knowing progress may be slow, effects uncertain, and benefits not guaranteed. Still, they show up for science again and again, enduring long clinic visits and difficult procedures with the belief that the work truly matters—and with the hope their efforts will lead to better treatments and outcomes for future generations.
At Rho, we execute Parkinson’s clinical trials with that trust and commitment in mind. Our deep understanding of the disease—physiologically, scientifically, and medically—guides every decision we make. Whether it’s patient selection, study design, or vendor management, we work closely with our partners to ensure studies are conducted with respect for the people at the center of them. Because when patients invest so much in scientific progress, strong execution shouldn’t be optional…it’s what they deserve.
Why Parkinson’s Research Is Different
Parkinson’s disease doesn’t follow a set script, and no two patient journeys are the same. Symptoms evolve unpredictably, response to treatment varies, and progression and outcomes are deeply personal. For participants in Parkinson’s disease clinical trials, this means navigating a demanding disease while also contributing to research that asks even more of them. Their investment is an act of generosity that carries the future of Parkinson’s research forward. That level of dedication raises the standard for how clinical trials should be run. At Rho, we take this responsibility seriously. We bring empathy, reliability, and adaptability to Parkinson’s clinical research to honor the patients behind the data points and the future they are helping to build—not just for themselves, but for everyone.
We’re built to solve the challenges that define Parkinson’s research
Spotlight: Parkinson’s Disease Trial Readiness Diagnostic
Is your Parkinson’s trial structured to support patients, caregivers, and investigators? These studies are particularly complex, but they are also significant commitments for everyone involved.
Parkinson’s trials challenge every operational decision you make from day one. Whether it’s your site strategy, timeline management, or long-term continuity plan, teams must execute and perform under real-world conditions. Because behind every Parkinson’s protocol is a highly engaged community placing their trust in the process—and it’s critical to honor their commitment with a study that is stable, interpretable, and achievable over time.
If you need an honest snapshot of your execution readiness, then this diagnostic is for you. Let’s build a Parkinson’s study that’s scientifically sound and delivers meaningful results.
Parkinson’s disease clinical trial capabilities
Parkinson’s network insight
Study design that solves PD challenges
Proven clinical trial execution
Protocols built around people
Parkinson’s disease research FAQ
What makes Parkinson’s trials uniquely challenging?
Parkinson’s trials are complex because each person’s experience with the disease is unique. Determining how to measure symptoms, maintain rater consistency, and manage site dynamics all influence outcomes. These studies are long and nuanced, requiring sustained commitment from investigators, caregivers, patients, and sponsors. Effective protocols follow real PD patient flow and disease progression. Addressing upstream risks early helps keep the study on track—small inconsistencies can compound over time, making proactive prevention essential.
What can commonly go wrong in Parkinson’s trials?
One of the key challenges in Parkinson’s trials is distinguishing disease modification from symptomatic therapy, and protocols must be designed to support that distinction. Inter-rater variability also creates noise in clinical assessments. Enrollment is often slow, especially in treatment-naïve cohorts, so expectations and timelines need to reflect that reality. Because Parkinson’s is a long and progressive illness, measures must be structured to capture the progression over time. In more lengthy studies, caregiver fatigue can affect adherence, contributing to higher patient dropout rates.
How are Parkinson’s trials effected by operational realities?
Parkinson’s disease trials are like marathons: patience, precision, and realistic timelines are essential. Treatment-naïve PD populations enroll slowly, much like in rare disease research. High-profile physicians are often the first choice for patients, which can further slow early enrollment. Large, well-known academic centers produce excellent data but typically require longer startup times. A balanced site network—combining major academic centers with smaller, faster-moving sites—delivers the best overall performance.
What stands out about Parkinson’s patients?
Successful teams understand the full journey of Parkinson’s patients—from first symptoms to diagnosis, to treatment, and beyond. Participants are often highly motivated, altruistic, and committed to advancing research. For many, taking part in a trial is a way to leave a legacy and contribute to future generations. They are willing to participate in and endure lengthy procedures, and their dedication supports retention. Studies must be designed to honor their time and meet their needs.
Why do Parkinson’s trials require specialized expertise?
Parkinson’s science is unique, and effective research calls for teams with deep knowledge of the disease. Patient pathways differ dramatically from other indications—such as pain—and that expertise informs every step of a study, including the design, strategy, patient criteria and selection, vendor oversight, site planning, and operational decisions. The long, progressive nature of Parkinson’s requires measures that capture that progression over time. Wearables, sensors, and scale selection must be used thoughtfully and with a clear purpose.
Rho is advancing Parkinson’s disease research, with experience across 50+ neurology studies at 370+ sites over the last five years—including eight focused on Parkinson’s disease. These studies are complex and demand strong end-to-end execution. But the people behind the work are what matter most. With more than 30 highly experienced Parkinson’s disease team members at Rho, we collaborate with organizations like the Michael J. Fox Foundation, Parkinson’s Foundation, and David Phinney Foundation to ensure research is both scientifically rigorous and genuinely centered on the Parkinson’s community.
Related insights & resources
Parkinson’s disease trials are complex. Execute them with confidence.
No matter where you are in your clinical program, Rho brings the experience and judgement to support the people at the heart of every study.
